S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.46
+1.78
+10.67%
MAZE · Maze Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Maze Therapeutics Inc (MAZE)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$32.55
+0.10
(+0.32%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$32.55
$31.56
$32.96
52-WEEK RANGE
$32.55
$21.95
$53.65
What's happening
- MAZE is up 0.32% today, trading at $32.55. — Live quote
- Volume today (101,936) is well below its 3-month average of 675,820. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.76 actual vs. $-0.75 estimated (-1.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MAZE
-21.36%
vs S&P 500
-34.73%
1-YEAR RETURN
MAZE
+10.37%
vs S&P 500
-4.80%
6-MONTH RETURN
MAZE
+15.98%
3-MONTH RETURN
MAZE
+14.36%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.76
Est. $-0.75
MISS -1.5%
2026-04-26 (Q1 2026)
$-0.45
Est. $-0.56
BEAT +19.1%
2026-01-26 (Q4 2025)
$-0.65
Est. $-0.73
BEAT +10.7%
2025-10-26 (Q3 2025)
$-0.66
Est. $-0.72
BEAT +8.7%
Valuation Measures & Ratios
Enterprise Value4$1.65B
Forward P/E5—
PEG Ratio6-0.25
Price / Sales (TTM1)10.80
Price / Book73.64
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-34.94%
Return on Assets (ROA9)-30.18%
Avg Volume (3M)675,820
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.76B | $1.60B | $1.18B | $545.0M | $311.0M |
| P/E | -13.24 | -13.26 | -9.76 | 11.39 | 6.34 |
| Price/Book | 3.88 | 4.69 | 3.12 | 2.08 | 1.06 |
| ROE | -29.29% | -35.34% | -31.97% | 18.24% | 16.79% |
| ROA | -24.96% | -28.77% | -28.74% | 15.76% | 14.73% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,565,330
Change from Prior Settlement+15.62%
% of Float—
Days to Cover (Short Ratio)6.07
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +10.4%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MAZE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $20.0M | — | $0 | — | $2.5M | $165.0M | — |
| Operating income | -$48.0M | -$26.6M | -$33.0M | -$36.5M | -$35.4M | -$24.2M | $139.6M | -$28.0M |
| Net income | -$44.7M | -$24.2M | -$30.1M | -$33.7M | -$32.8M | -$24.8M | $139.1M | -$32.5M |
| EPS (diluted) | $-0.76 | $-0.45 | $-0.66 | $-0.77 | $-1.15 | $-10.25 | $3.22 | $-13.91 |
| EPS (basic) | $-0.76 | $-0.45 | $-0.66 | $-0.77 | $-1.15 | $-10.25 | $5.92 | $-13.91 |
| Operating margin | — | -$133 | — | — | — | -$969 | $85 | — |
| Net margin | — | -$121 | — | — | — | -$990 | $84 | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $531.6M | $419.7M | $397.1M | $422.1M | $303.5M | $332.8M | $240.5M | — |
| Total liabilities | $78.5M | $78.0M | $42.2M | $42.6M | $41.3M | $40.8M | $43.6M | — |
| Stockholders' equity | $453.1M | $341.7M | $355.0M | $379.4M | $262.2M | $292.1M | -$311.2M | — |
| Total current assets | $420.4M | $379.8M | $349.7M | $391.3M | $271.1M | $299.7M | $201.7M | — |
| Total current liabilities | $23.0M | $21.2M | $22.6M | $22.1M | $19.9M | $18.6M | $20.7M | — |
| Cash & equivalents | $202.6M | $198.8M | $189.2M | $316.8M | $264.5M | $294.4M | $196.8M | $149.6M |
| Marketable securities (current) | $208.4M | $153.6M | $152.7M | $67.2M | — | — | — | — |
| Accounts receivable | — | $20.0M | — | — | — | — | — | — |
| Marketable securities (non-current) | $83.8M | $10.6M | $18.1M | — | — | — | — | — |
| Property, plant & equipment | $4.4M | $4.7M | $5.0M | $5.5M | $6.0M | $6.3M | $6.7M | — |
| Other non-current assets | $3.5M | $4.3M | $3.0M | $3.2M | $3.6M | $3.2M | $7.9M | — |
| Accounts payable | $2.2M | $4.0M | $1.8M | $2.9M | $3.7M | $2.4M | $1.9M | — |
| Short-term debt | $0 | $0 | — | — | — | — | — | — |
| Long-term debt | $39.0M | $38.8M | — | — | — | — | — | — |
| Other non-current liabilities | — | $388.0K | $1.1M | $1.1M | $1.1M | $1.0M | $969.0K | — |
| Common stock & paid-in capital | $56.0K | $50.0K | $49.0K | $48.0K | $44.0K | $44.0K | $2.0K | — |
| Retained earnings | -$558.5M | -$513.8M | -$489.5M | -$455.0M | -$424.9M | -$391.2M | -$358.4M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.1M | -$39.1M | -$27.7M | -$24.6M | -$30.1M | -$29.5M | -$22.5M | -$23.2M |
| Investing cash flow | -$128.5M | $6.3M | -$103.4M | -$66.9M | -$393.0K | -$299.0K | -$605.0K | -$103.0K |
| Financing cash flow | $147.4M | $42.4M | $3.6M | $143.8M | $612.0K | $127.4M | $70.3M | -$2.1M |
| Free cash flow | -$15.2M | -$39.2M | -$27.8M | -$24.7M | -$30.4M | -$29.8M | -$23.1M | -$23.3M |
| Capital expenditures | $107.0K | $93.0K | $34.0K | $68.0K | $393.0K | $299.0K | $605.0K | $103.0K |
| Share-based compensation | $9.2M | $7.1M | $6.1M | $3.9M | $3.2M | $3.2M | $2.9M | $2.3M |
| Change in accounts payable | -$1.8M | $2.2M | -$1.1M | -$748.0K | $1.3M | $579.0K | $821.0K | -$1.2M |
| Purchases of investments | $162.4M | $23.6M | $120.9M | $66.8M | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Revenue | — | $167.5M |
| Operating income | -$142.9M | $57.6M |
| Net income | -$131.1M | $52.2M |
| EPS (diluted) | $-3.05 | $1.25 |
| EPS (basic) | $-3.05 | $1.42 |
| Operating margin | — | $34 |
| Net margin | — | $31 |
Balance sheet
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Total assets | $397.1M | $240.5M |
| Total liabilities | $42.2M | $43.6M |
| Stockholders' equity | $355.0M | -$311.2M |
| Total current assets | $349.7M | $201.7M |
| Total current liabilities | $22.6M | $20.7M |
| Cash & equivalents | $189.2M | $196.8M |
| Marketable securities (current) | $152.7M | — |
| Marketable securities (non-current) | $18.1M | — |
| Property, plant & equipment | $5.0M | $6.7M |
| Other non-current assets | $3.0M | $7.9M |
| Accounts payable | $1.8M | $1.9M |
| Other non-current liabilities | $1.1M | $969.0K |
| Common stock & paid-in capital | $49.0K | $2.0K |
| Retained earnings | -$489.5M | -$358.4M |
Cash flow
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Operating cash flow | -$111.9M | $76.0M |
| Investing cash flow | -$171.0M | -$1.1M |
| Financing cash flow | $275.3M | $92.8M |
| Free cash flow | -$112.7M | $74.8M |
| Capital expenditures | $794.0K | $1.1M |
| Share-based compensation | $16.4M | $9.6M |
| Change in accounts payable | -$27.0K | -$204.0K |
| Purchases of investments | $187.7M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MAZE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers85.0%
Shares Outstanding58,995,934
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,032,915 | $150.2M | 8.53% | +10.2% | 2026-08-14 |
| TRV GP IV, LLC | 4,473,958 | $133.5M | 7.58% | +0.0% | 2026-08-07 |
| ARCH Venture Management, LLC | 4,120,053 | $123.0M | 6.98% | +0.0% | 2026-08-14 |
| Deep Track Capital, LP | 3,732,569 | $111.4M | 6.33% | +7.3% | 2026-08-14 |
| BlackRock, Inc. | 3,502,841 | $104.5M | 5.94% | +36.3% | 2026-08-07 |
| Jupiter Topco LLC | 3,408,045 | $101.8M | 5.78% | +0.0% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 2,603,682 | $77.7K | 4.41% | +0.0% | 2026-08-14 |
| Logos Global Management LP | 1,935,000 | $57.7M | 3.28% | +56.7% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,778,222 | $53.1M | 3.01% | +23.9% | 2026-06-30 |
| a16z Capital Management, L.L.C. | 1,702,225 | $50.8M | 2.89% | +0.0% | 2026-08-14 |
| Venrock Adviser, LLC | 1,602,034 | $47.8M | 2.72% | +0.0% | 2026-08-14 |
| Alphabet Inc. | 1,388,583 | $41.4M | 2.35% | +0.0% | 2026-08-06 |
| BRAIDWELL LP | 1,140,040 | $34.0M | 1.93% | +0.0% | 2026-08-14 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1,107,814 | $33.1M | 1.88% | +197.0% | 2026-08-14 |
| FMR LLC | 1,056,959 | $31.5M | 1.79% | +22.3% | 2026-08-13 |
| General Catalyst Group Management, LLC | 1,035,910 | $30.9M | 1.76% | +0.0% | 2026-08-14 |
| State Street Corp | 997,533 | $29.8M | 1.69% | +56.7% | 2026-08-07 |
| Jpmorgan Chase & Co | 964,011 | $28.0M | 1.63% | +1549.4% | 2026-08-12 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 954,886 | $28.5M | 1.62% | +50.1% | 2026-08-14 |
| TRV GP V, LLC | 950,800 | $28.4M | 1.61% | +0.0% | 2026-08-07 |
| MARSHALL WACE, LLP | 914,572 | $27.3M | 1.55% | +194.4% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 858,054 | $25.6M | 1.45% | +43.0% | 2026-08-12 |
| CITADEL ADVISORS LLC | 852,676 | $25.4M | 1.45% | +9.9% | 2026-08-14 |
| Casdin Capital, LLC | 843,857 | $25.2M | 1.43% | +11.2% | 2026-08-14 |
| ArrowMark Colorado Holdings LLC | 767,383 | $22.9M | 1.30% | +0.0% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-22 to 2026-10-01
Recent transactions
- Insiders have net sold 311,960 shares over the last 182 days, across 0 purchases and 41 sales.
- Most recent: Coloma Jason V (Chief Executive Officer) — Open market sale of 2,593 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)311,960 sh(41 txns)
Net Shares-311,960
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Coloma Jason V | Chief Executive Officer | Open market sale | 2026-10-01 | 2,593 |
| Bernstein Harold | President, R&D & CMO | Option exercise | 2026-10-01 | 16,141 |
| Dandekar Atul | CSBO | Option exercise | 2026-09-29 | 7,500 |
| Courtney Phillips | GC and Corp. Secretary | Open market sale | 2026-09-03 | 1,990 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 2,593 | $27.02 |
| 2026-10-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 31,908 | $27.02 |
| 2026-10-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 16,141 | $10.42 |
| 2026-10-01 | Bernstein Harold | President, R&D & CMO | Open market sale | 16,141 | $26.93 |
| 2026-09-29 | Dandekar Atul | CSBO | Option exercise | 7,500 | $10.42 |
| 2026-09-29 | Dandekar Atul | CSBO | Open market sale | 7,500 | $27.06 |
| 2026-09-04 | Bernstein Harold | President, R&D & CMO | Open market sale | 9,705 | $26.22 |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Open market sale | 1,990 | $26.01 |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Open market sale | 22 | $25.78 |
| 2026-09-03 | Dandekar Atul | CSBO | Open market sale | 3,207 | $26.01 |
| 2026-09-03 | Dandekar Atul | CSBO | Open market sale | 36 | $25.81 |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 11,282 | $26.01 |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 129 | $25.77 |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Open market sale | 5,130 | $26.01 |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Open market sale | 59 | $25.78 |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Open market sale | 1,738 | $26.38 |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Open market sale | 243 | $27.12 |
| 2026-09-02 | Dandekar Atul | CSBO | Open market sale | 2,800 | $26.38 |
| 2026-09-02 | Dandekar Atul | CSBO | Open market sale | 391 | $27.12 |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Open market sale | 9,852 | $26.38 |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Open market sale | 1,375 | $27.12 |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Open market sale | 4,481 | $26.38 |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Open market sale | 625 | $27.12 |
| 2026-09-01 | Courtney Phillips | GC and Corp. Secretary | Option exercise | 11,000 | $0.00 |
| 2026-09-01 | Dandekar Atul | CSBO | Option exercise | 12,500 | $0.00 |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 2,593 | $26.31 |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 31,908 | $26.29 |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Option exercise | 50,000 | $0.00 |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 16,141 | $10.42 |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Open market sale | 16,141 | $26.36 |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 20,000 | $0.00 |
| 2026-08-28 | Dandekar Atul | CSBO | Option exercise | 7,500 | $10.42 |
| 2026-08-28 | Dandekar Atul | CSBO | Open market sale | 7,500 | $27.58 |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Option exercise | 16,142 | $10.42 |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Open market sale | 16,142 | $27.61 |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 2,439 | $26.71 |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 154 | $27.09 |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 30,304 | $26.71 |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Open market sale | 1,604 | $27.09 |
| 2026-07-29 | Dandekar Atul | CSBO | Option exercise | 7,500 | $10.42 |
| 2026-07-29 | Dandekar Atul | CSBO | Open market sale | 7,100 | $27.31 |
| 2026-07-29 | Dandekar Atul | CSBO | Open market sale | 400 | $27.89 |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Option exercise | 14,609 | $10.42 |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Open market sale | 13,409 | $29.86 |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Open market sale | 1,200 | $30.34 |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 2,593 | $29.98 |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 30,311 | $29.95 |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Open market sale | 1,597 | $30.44 |
| 2026-06-29 | Dandekar Atul | CSBO | Option exercise | 7,500 | $10.42 |
| 2026-06-29 | Dandekar Atul | CSBO | Open market sale | 7,500 | $28.02 |
| 2026-06-23 | Coloma Jason V | Chief Executive Officer | Open market sale | 23,865 | $26.05 |
| 2026-06-22 | Coloma Jason V | Chief Executive Officer | Open market sale | 1,953 | $26.00 |
| 2026-06-22 | Coloma Jason V | Chief Executive Officer | Open market sale | 2,040 | $26.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:43 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
Recent news
Headlines about MAZE (Maze Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Best Pumpkin Patches and Corn Mazes Near Atlanta This Fall
Modern Luxury · 2026-10-20 -
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Is Maze Therapeutics (MAZE) Undervalued Or Is Its Recent Rebound Already Priced In?
Simply Wall Street · 2026-10-19 -
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history
Yahoo Finance UK · 2026-10-19 -
La Union Maze s 2026 Season Brings Fall Fun Near El Paso
KFOX · 2026-10-19 -
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
Yahoo · 2026-10-19 -
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Yahoo · 2026-10-19 -
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
Yahoo · 2026-10-19
No headlines in this category right now — try “All”.